Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(2 sites)
China
Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing Municipality Jilin Cancer Hospital, Changchun, Jilin